Replies to post #111414 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

The dropout question regarding the charts would be worth putting to Anavex IR, or perhaps you did?

[Gernee20]

Flash I did not make an assumption. It clearly says data includes all evaluable patients. A dropped patient is not evaluable, being they have dropped from the trial.

Patients responding well, and patients not responding well, could have dropped out. Anavex did not control who dropped, so implying they are showing data without dropouts, you are also implying the dropouts were not responding, hence providing higher avgs and better results. Let's be real, if patients were taking 10ml doses, and they were taking 10ml doses, we would expect those patients to decline being we know it takes 14ml to receive positive benefit from 2-73, and, it's these patients who would most likely dropout being 2-73 was not helping them. So, it's very possible the dropouts were on low doses and continuing the AD decline, for different reasons dropped out of the trial, and in turn the data represented higher avgs on this particular graph.

Can I ask, what's your point here?

[apostrophe]

re:"Taking Anavex completely out of the equation, if a biotech company (any "other" biotech company) leaves off critical information from their presentations, would it be wise for investors to fill in the blanks with the most positive method possible? "

Regardless, the current standard of care is 100% fail.

Using your schoolchildren class example. The competing class is all "F". It would nice to be all 'A's but unlike big pharma shooting for the moon to get "D-", it seems obvious we are passing grade at least at this point. Regardless if a few students skip class.

[McMagyar]

F1
It is Safe..

Exploratory Efficacy was the point.
Point made.

You are arguing over minutia.
In the end your point will be pointless..